$WW

DellaFortuna Felicia purchased $19K of WW

DellaFortuna Felicia (CFO & Member, IOCE) purchased 1,500 shares of WW INTERNATIONAL, INC. (WW) at $12.68 on 2026-05-22.

Original reporting
SEC EDGAR · DellaFortuna Felicia
Published May 27, 2026, 8:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$WW
Bullish
medium confidence
Mentioned
$WW
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WWBullishLow
01

Why it matters

An officer/direct insider open-market purchase can modestly support sentiment, but without accompanying company-specific fundamentals it is unlikely to materially change valuation.

02

Market read

Traders may note the insider buy as a small positive signal, but the lack of new fundamentals limits trading edge.

03

What to watch

No 10b5-1 plan is cited, but the filing alone doesn’t confirm intent, and the article lacks context on prior insider activity or total holdings changes beyond this lot.

Relevance 6/10Timing: Immediate (new Form 4 filed 2026-05-27) but unlikely to drive sustained repricing without additional catalysts.

Background

The article is a SEC Form 4 insider transaction disclosure for WW International, Inc.

Company-level read

Ticker impact

$WWBullishMedium confidence
Context

WW International CFO Felicia DellaFortuna filed an open-market purchase of 1,500 shares at $12.6750 on 2026-05-22.

Expected impact

Mild positive bias; any reaction is likely short-lived unless followed by larger buys or fundamental catalysts.

Evidence & confidence

Form 4 insider purchases can signal confidence, but the article provides no new operational or financial information and the disclosed size/value is modest.

Market effects

Minimal; insider buying in a single company typically does not reset sector expectations.

None indicated; transaction is company-specific and US-listed.

None indicated; no cross-border deal or regulatory event mentioned.

Counterpoint

The purchase may reflect routine portfolio rebalancing or personal liquidity needs rather than a forward-looking view.

Key entities

  • WW International, Inc.

    Subject of the Form 4 insider purchase by CFO & IOCE Felicia DellaFortuna.

  • Felicia DellaFortuna

    CFO & Member (IOCE) who purchased 1,500 shares at $12.6750 on 2026-05-22.

Related articles

$WWMed

WW International Q2 Earnings Call Highlights

WW International (NASDAQ:WW) reported Q2 average revenue per user up 10.2% YoY. Clinical subscription revenue rose 30.4% to $39.9M, while behavioral fell 22.7% to $121.5M. Gross margin was 70.3% (adjusted 73.6%). WW ended with $101.5M cash, repaid debt, and reaffirmed 2026 revenue $620M-$635M and adjusted EBITDA $105M-$115M.

$WWMed

WeightWatchers’s (NASDAQ:WW) Q2 CY2026: Beats On Revenue

WeightWatchers (NASDAQ:WW) reported Q2 CY2026 revenue of $162.3 million, down 14.2% year on year, but 2% above Wall Street estimates, according to the company. Full-year revenue guidance is $627.5 million at the midpoint, 0.7% below analysts’ estimates. GAAP profit was $1.41 per share above consensus; shares fell 1.3% to $15.23 after the report.

$WWMed

WW INTERNATIONAL, INC. (WW): Results of Operations and Financial Condition

WW INTERNATIONAL, INC. (WW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d15116dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Weight Watchers Announces Second Quarter 2026 Results Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousan

$WWMedAI 8/10

Why WeightWatchers (WW) Stock Is Trading Up Today

WeightWatchers (NASDAQ: WW) shares rose 6.3% in the afternoon after the company said its Weight Watchers Med+ program is now available through Eli Lilly’s digital platform, LillyDirect. The program pairs GLP-1 prescription obesity drugs with behavioral, nutritional, and lifestyle support. The stock is down 45.5% year to date, at $17.13.